@article{article, title  = {{Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA).}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2013}},

 month = {{2}},

 author = {{Vogelzang NJ and Parker C and Nilsson S and Coleman RE and O'Bryan-Tear CG and Shan M and Sartor AO}},

 doi = {{10.1200/jco.2013.31.6_suppl.11}},

 volume = {{31}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{6_suppl}},

 pages = {{11-11}},

 note = {{Accessed on 2025/10/10}}}